Results 211 to 220 of about 41,710 (302)

A case of immunoglobulin G4-related kidney disease manifesting after dipeptidyl peptidase-4 inhibitor treatment. [PDF]

CEN Case Rep
Ubara Y, Takeuchi T, Hasegawa E, Sekine A, Inoue N, Tanaka K, Mizuno H, Oba Y, Yamanouchi M, Suwabe T, Kono K, Kinowaki K, Ohashi K, Yamaguchi Y, Sawa N, Wada T.   +15 more
europepmc   +1 more source

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications [PDF]

, 2015

core   +1 more source

Therapeutic Potential of Origanum majorana L. Essential Oil in Diabetes Mellitus: Insights From GC–MS Characterization, In Vivo Hypoglycaemic Studies, and In Silico Analyses

Chemistry &Biodiversity, Volume 23, Issue 5, May 2026.
Exploring the chemical profile and biological property of O. majorana EO. ABSTRACT Diabetes mellitus is a widespread metabolic disorder characterized by impaired glucose regulation. This study investigated the chemical composition and antidiabetic potential of Origanum majorana essential oil (EO) using integrated in vitro, in vivo, and computational ...
Mahmoud Houas, Mohammed Larbi Benamor, Elhafnaoui Lanez, Yahia Bekkar, Lotfi Bourougaa, Ouafa Boudebia, Rania Bouraoui, Aicha Adaika, Nafila Zouaghi, Salah Neghmouche Nacer, Lazhar Bechki, Touhami Lanez, Stefania Garzoli   +12 more
wiley   +1 more source

Association between dipeptidyl peptidase-4 inhibitor use and risk of Parkinson's disease among patients with diabetes mellitus: a retrospective cohort study. [PDF]

Aging (Albany NY)
Huang KH, Yang Y, Gau SY, Tsai TH, Lee CY.   +4 more
europepmc   +1 more source

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1265-1274, May 2026.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko, Philip C. M. Au, Michael Chun‐Yuan Cheng, Ching‐Lung Cheung, Ahhyung Choi, Miyuki Hsing‐Chun Hsieh, Han Eol Jeong, Edward Chia‐Cheng Lai, Brian Meng‐Hsun Li, Kenneth K. C. Man, Jeremy A. Rassen, Daniel Hsiang‐Te Tsai, Shirley V. Wang, Ian C. K. Wong, Ju‐Young Shin, Sohee Park   +15 more
wiley   +1 more source

Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Kamrul-Hasan ABM, Dutta D, Nagendra L, Sharma M, Patra S, Bhattacharya S.   +5 more
europepmc   +1 more source

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease. [PDF]

Lab Invest
Al Tuhaifi T, Zhong J, Yang HC, Fogo AB.
europepmc   +1 more source

Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
Ecnoglutide, a once‐weekly GLP‐1 receptor agonist, significantly improves glycaemic control and promotes meaningful weight loss compared with placebo in type 2 diabetes. This systematic review and meta‐analysis of four RCTs demonstrates favourable efficacy with mostly mild gastrointestinal adverse events and no increase in serious safety concerns ...
Mukesh Kumar, Sumet Kumar, Sheikh Muhammad Ebtehaj Ali, Hadia Qazi, Arshia Arif Janjua, Hanzlah Ahmed, Rayan Babar, Rumaisa Imtiaz Sheikh, Laksh Kumar, Sana Mohammad Ali, Fatima Hanif, Khizra Gul, Ayesha Sarwar Ali, Shehzadi Umme Rubab Bukhari, Adarsh Raja, Aayush Chaulagain   +15 more
wiley   +1 more source

Investigation of Glucose Metabolism by Continuous Glucose Monitoring and Validation of Dipeptidyl Peptidase 4 Inhibitor Use in Patients with Myotonic Dystrophy Type 1. [PDF]

J Clin Med
Takada H, Matsumura T, Shimamura H, Matsui M, Kon S, Fukumoto A, Kubota T, Yoshida K, Iwahashi H, Takahashi MP.   +9 more
europepmc   +1 more source